Corona virus disease 2019 (COVID-19) refers to a type of pneumonia caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Sixty million confirmed cases have been reported worldwide until November 29, 2020. Unfortunately, the novel coronavirus is extremely contagious and the mortality rate of severe and critically ill patients is high. Thus, there is no definite and effective treatment in clinical practice except for antiviral therapy and supportive therapy. Mesenchymal stem cells (MSCs) are not only characterized by low immunogenicity and homing but also have anti-inflammatory and immunomodulation characteristics. Furthermore, they can inhibit the occurrence and development of a cytokine storm, inhibit lung injury, and exert antipulmonary fibrosis and antioxidative stress, therefore MSC therapy is expected to become one of the effective therapies to treat severe COVID-19. This article will review the possible mechanisms of MSCs in the treatment of severe COVID-19.

中文翻译：

---

重型COVID-19的间充质干细胞治疗研究进展。

2019年冠状病毒疾病（COVID-19）是指由严重急性呼吸系统综合症冠状病毒2（SARS-CoV-2）感染引起的一种肺炎。到2020年11月29日，全世界已报告了六千万例确诊病例。不幸的是，新型冠状病毒具有极强的传染性，重症和重症患者的死亡率很高。因此，除了抗病毒治疗和支持治疗外，在临床实践中没有确定有效的治疗方法。间充质干细胞（MSCs）不仅具有低免疫原性和归巢特性，而且还具有抗炎和免疫调节特性。此外，它们还可以抑制细胞因子风暴的发生和发展，抑制肺损伤，并发挥抗肺纤维化和抗氧化应激的作用，因此，预期MSC疗法将成为治疗严重COVID-19的有效疗法之一。本文将回顾MSCs治疗严重COVID-19的可能机制。